2023
Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study. Addictive Behaviors 2023, 140: 107615. PMID: 36640662, PMCID: PMC9911383, DOI: 10.1016/j.addbeh.2023.107615.Peer-Reviewed Original ResearchConceptsSmoking-related illnessesNegative drug effectsNicotine clearanceOvernight abstinenceNicotine infusionDrug effectsMentholated cigarettesWhite individualsBlack individualsAcute pharmacologic effectsSmoking-related morbiditySmoking-related diseasesAdministration of nicotineSmoking-related outcomesSubjective drug effectsShort-term abstinenceLower ratesTrend level differenceLarge racial disparitiesNicotine administrationNicotine dosesTrend-level significancePharmacologic effectsTreatment strategiesOutcome measures
2021
Individual Differences in the Associations Between Risk Factors for Alcohol Use Disorder and Alcohol Use-Related Outcomes
Haeny AM, Gueorguieva R, Jackson A, Morean ME, Krishnan-Sarin S, DeMartini KS, Pearlson GD, Anticevic A, Krystal JH, O’Malley S. Individual Differences in the Associations Between Risk Factors for Alcohol Use Disorder and Alcohol Use-Related Outcomes. Psychology Of Addictive Behaviors 2021, 35: 501-513. PMID: 34110841, PMCID: PMC9211405, DOI: 10.1037/adb0000733.Peer-Reviewed Original Research
2019
Examining Race as a Predictor and Moderator of Treatment Outcomes for Binge-Eating Disorder: Analysis of Aggregated Randomized Controlled Trials
Lydecker JA, Gueorguieva R, Masheb R, White MA, Grilo CM. Examining Race as a Predictor and Moderator of Treatment Outcomes for Binge-Eating Disorder: Analysis of Aggregated Randomized Controlled Trials. Journal Of Consulting And Clinical Psychology 2019, 87: 530-540. PMID: 31008634, PMCID: PMC6589831, DOI: 10.1037/ccp0000404.Peer-Reviewed Original ResearchConceptsBinge-eating disorderWhite participantsCognitive behavioral therapySelf-report measuresTreatment outcomesBinge-eating remissionModerate treatment outcomeBinge Eating DisorderBinge-eating episodesMain effectBlack participantsWeight lossBehavioral weight lossEvidence-based treatmentsLower depressionTreatment researchRandomized Controlled TrialsBetter treatment outcomesControl conditionParticipantsControlled TrialsMultimodal treatmentPercent weight lossPatient groupModerator
2014
Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: Randomized placebo-controlled clinical trial of self-help and medication
Grilo CM, Masheb RM, White MA, Gueorguieva R, Barnes RD, Walsh BT, McKenzie KC, Genao I, Garcia R. Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: Randomized placebo-controlled clinical trial of self-help and medication. Behaviour Research And Therapy 2014, 58: 1-9. PMID: 24857821, PMCID: PMC4074556, DOI: 10.1016/j.brat.2014.04.002.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Obesity AgentsBinge-Eating DisorderBlack or African AmericanBody WeightCognitive Behavioral TherapyCombined Modality TherapyCyclobutanesDouble-Blind MethodFemaleHispanic or LatinoHumansMaleMiddle AgedObesityPrimary Health CareSelf CareTime FactorsTreatment OutcomeWhite PeopleYoung AdultConceptsSelf-help cognitive behavioral therapyDiverse obese patientsAnti-obesity medicationsObese patientsModerate clinical outcomePercent weight lossTime interaction effectsWeight lossClinical outcomesPrimary careRandomized placebo-controlled clinical trialSecond placebo-controlled trialPlacebo-controlled clinical trialAcute weight lossPlacebo-controlled trialDouble-blind fashionDiscontinuation of medicationPrimary care settingWeight loss maintenanceSpecialist treatment centresTreatment of bingeDiverse patient groupsSelf-help CBTBinge-eating frequencyDemographic factorsPharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias AJ, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal On Addictions 2014, 23: 288-293. PMID: 24724887, PMCID: PMC4600600, DOI: 10.1111/j.1521-0391.2014.12102.x.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DeterrentsAlcoholismDiagnosis, Dual (Psychiatry)DisulfiramDopamine beta-HydroxylaseDrug Therapy, CombinationFemaleGenotypeHeterozygoteHumansMaleMental DisordersMiddle AgedNaltrexoneNarcotic AntagonistsPolymorphism, Single NucleotideReceptors, Opioid, muTreatment OutcomeVeteransWhite PeopleConceptsAllele carriersHeavy drinkingCo-occurring alcohol dependenceT allele carriersAlcohol-dependent subjectsAD treatment responseTreatment of individualsPrimary outcomePharmacogenetic interactionsHigher overall rateTreatment responseAxis INaltrexoneT carriersEuropean-American subjectsOPRM1 rs1799971Favorable responseMore abstinenceAlcohol dependenceDependent subjectsDBH rs1611115DisulfiramGenotyped subjectsAbstinenceLess drinking